Palisade Bio Shares Are Trading Higher After the Company Announced the Presentation of Data From Two Studios Showing Ex Vivo Bioactivation of PALI-2108 in the Treatment of Ulcerative Colitis.
Palisade Bio Shares Are Trading Higher After the Company Announced the Presentation of Data From Two Studios Showing Ex Vivo Bioactivation of PALI-2108 in the Treatment of Ulcerative Colitis.
帕利塞德生物股票交易较高,公司宣布来自两个研究所的数据展示PALI-2108在治疗溃疡性结肠炎中的离体生物活化。
Palisade Bio Shares Are Trading Higher After the Company Announced the Presentation of Data From Two Studios Showing Ex Vivo Bioactivation of PALI-2108 in the Treatment of Ulcerative Colitis.
Palisade Bio宣布两家工作室公布的数据显示,在溃疡性结肠炎的治疗中体外生物激活了 PALI-2108,此后,该公司股价走高。